Azurity acquires Covis Pharma from existing investors
Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary. The acquisition is aimed at improving Azurity’s medicine delivery offerings globally. It will broaden Azurity’s therapeutic portfolio with 10 complex dosage forms and nine therapeutic areas and extend its worldwide reach to more than 50 nations. The acquisition complements…